Medicinal and Bioinorganic Chemistry Research Group Medicinal and Bioinorganic Chemistry Research Group (QMEDBIN) Research and Doctoral Institute Faculty of Medicine and Health Sciences Central University of Chile CHILE Full professor and researcher at the Research and Doctoral Institute, Faculty of Medicine and Health Sciences at the Central University of Chile (UCEN, Chile). He was a professor and researcher at the University of Chile (Chile) and the University of Santiago de Compostela (USC, Spain), while he continues as an associate researcher at the Faculty of Pharmacy (USC) in the field of Natural Products - Medicinal Chemistry against CNS diseases and experimental studies on drug delivery systems. From these lines of research, more than 180 high-impact scientific articles have been generated in the fields of Chemistry, Pharmacy, and Nanotechnology, compiled in several journals. On the basis of the excellent experimental results, and of direct application in the scope of the health, such results have been protected in more than 9 (European) protection patents and PCT (Patent Cooperation Treaty) that cover the scope of the applied nanomedicine in neuro-degenerative and parasitic diseases. At the present time, he is International Referee of Research Projects in the fields of Biomedicine, in Argentina and Chile (FONCYT and FONDECYT, respectively), and Spain for the National Agency of Evaluation and Prospective (ANEP). He is Editor / Editorial Board member of the following journals; Molecules, International Journal of Nanomedicine, Journal of Nanomedicine and Nanotechnology, Archives of Natural Biological Research, Frontiers in Pharmacology, Mini-Reviews in Medicinal Chemistry, Current Medicinal Chemistry, Oxidative Medicine and Cellular Longevity and Current Topics in Medicinal Chemistry.

Dentro de las actividades de investigación realizadas, se pueden describir dos líneas de investigación principales; 1) Síntesis de compuestos de fuentes naturales o vías sintéticas con actividad farmacológica (disfunciones neurodegenerativas y trastornos del comportamiento como enfermedades de Parkinson y Alzheimer y depresión-ansiedad, respectivamente), y enfermedades parasitarias (Malaria, Leishmania), y; 2) Síntesis de sistemas supramoleculares derivados de polímeros naturales/sintéticos para liberación controlada de fármacos.